Allergan announced it has submitted a Prior Approval Supplement for Restasis 0.05% to obtain marketing clearance for a multidose preservative-free formulation.According to the company press release, if the new presentation of Restasis (cyclosporine oph…
Author: Healio ophthalmology
Chairman delivers year’s industry highlights at OIS
LAS VEGAS — This year has been an innovative year in ophthalmology with several milestones being reached, including a number of FDA submissions and successful phase 3 clinical trials, according to Emmett T. Cunningham Jr., MD, PhD, MPH, who gave the “Chairman’s 2015 Year in Review” at the Ophthalmology Innovation Summit here. Spark Therapeutics reported clinical results for RPE-65, the first phase 3 clinical trial for gene therapy for the eye. AbbVie also reported positive phase 3 trial results for Humira (adalimumab) for treatment of noninfectious uveitis.
VIDEO: Change in business model expected to create positive impact
LAS VEGAS — At the Ophthalmology Innovation Summit, Joe Boorady, CEO of TearScience, discusses the recent changes to the company’s capital as well as price point for disposable applicators for the LipiView device.
Speaker: Ophthalmology entering next golden age of innovation
LAS VEGAS — Ophthalmology’s next golden age of innovation is comprised of three factors: the market for eye care, the ophthalmology ecosystem and where ophthalmology is from a scientific standpoint, according to Brent Saunders, president and CEO of Allergan.“There have been many golden ages of innovation in ophthalmology. When I started to look at the factors that led to a golden age of innovation, it occurred to me that we are on the cusp of entering a new or next golden age of innovation in eye care,” Saunders said during (Read more...)
VIDEO: Second Sight chairman discusses company’s latest innovations
LAS VEGAS — At the Ophthalmology Innovation Summit, Robert Greenberg, MD, chairman of Second Sight, discusses the company’s latest innovations for treating blindness, including information on the Argus II retinal prosthesis system.
VIDEO: Update on Allegro’s phase 2b clinical trials
LAS VEGAS — At the Ophthalmology Innovation Summit, Vicken Karageozian, MD, chief technical officer of Allegro Ophthalmics, discusses progress of the company’s Luminate (ALG-1001) program and gives an update on phase 2b clinical trials and use of the integrin peptide across multiple vitreoretinal indications, including vitreomacular traction, diabetic macular edema and posterior vitreous detachment.
VIDEO: New software facilitates patient follow-up care
LAS VEGAS — At the Ophthalmology Innovation Summit, John A. Hovanesian, MD, FACS, founder of MDbackline, discusses the advantages of the software’s automated patient contact system, which facilitates follow-up care and helps educate patients.
VIDEO: Small aperture inlay, IOL garnering good visual results
LAS VEGAS — At the Ophthalmology Innovation Summit, Nick Tarantino, OD, chief global clinical research and regulatory affairs officer for AcuFocus, discusses visual results achieved in presbyopia correction with the Kamra inlay as well as the IC-8 IOL in development.
VIDEO: Shire moves forward with lifitegrast in wake of OPUS 3 results
LAS VEGAS — At the Ophthalmology Innovation Summit, Robert Dempsey, vice president and head of ophthalmology at Shire, discusses the company’s plans moving forward for lifitegrast in dry eye treatment.
VIDEO: CEO shares new data on Dextenza
LAS VEGAS — At the Ophthalmology Innovation Summit, Amar Sawhney, PhD, president and CEO of Ocular Therapeutix, discusses the latest clinical trial data on Dextenza (sustained-release dexamethasone 0.4 mg) for ocular itching associated with allergic conjunctivitis.
Leaders who believe in promise of intraoperative aberrometry win Ophthalmology Innovation Award
LAS VEGAS — Two innovators who worked together to bring the latest generation of intraoperative aberrometry to surgeons were honored at the Ophthalmology Innovation Summit here.Moderator Richard L. Lindstrom, MD, said when introducing Daniel S. Durrie, MD, founder and president of Durrie Vision, and Thomas G. Frinzi, president and CEO of WaveTec Vision, as winners of the Ophthalmology Innovation Award, “It is certainly a pleasure for me, because I have known both of the winners this year for their entire careers.”
FDA accepts application for ThromboGenics’ studyof Jetrea in nonproliferative diabetic retinopathy
The FDA has accepted ThromboGenics’ investigational new drug application for the phase 2 CIRCLE study of ocriplasmin to treat nonproliferative diabetic retinopathy, according to a press release.The randomized, double-masked, sham-controlled, multicenter study will evaluate the efficacy and safety of multiple doses of Jetrea (ocriplasmin) in inducing total posterior vitreous detachment in patients with moderate to severe nonproliferative diabetic retinopathy. The trial will be conducted in the U.S. and several countries in Europe, the release said.
Alimera reports 188% increase in net revenue in third quarter
Alimera Sciences reported $6.9 million in net revenue in the third quarter, a 188% increase compared with $2.4 million reported in the same quarter of 2014, according to a press release. The increase was primarily attributed to the launch of Iluvien (f…
VIDEO: Options for minimally invasive strabismus surgery
NEW YORK — At OSN New York 2015, Rudy Wagner, MD, discusses the benefits of minimally invasive strabismus surgery.
Vision Medicines, Case Western enter licensing agreement for VM200 for Stargardt disease
Vision Medicines has entered into an exclusive worldwide licensing agreement with Case Western Reserve University for VM200, an oral small molecule drug candidate for the treatment of Stargardt disease, according to a press release. “We are enthusiastic about the potential for VM200 and have initiated investigational new drug application-enabling studies to advance VM200 into a phase 1/2 program for Stargardt disease in 2016,” Chris Varma, PhD, chairman and CEO of Vision Medicines, said in the release.
Regeneron reports $1.1 billion in revenue in third quarter
Regeneron reported $1.1 billion in total revenue in the third quarter compared with $726 million in the same quarter of 2014, according to a press release. The increase was partially attributed to an increase in net profit from commercialization of Eyl…
VIDEO: Speaker gives pearls for toric IOLS
NEW YORK — At OSN New York 2015, Elizabeth Yeu, MD, shares pearls for using toric IOLs for astigmatism correction.
Ophthotech reports $39.6 million net loss in third quarter
Ophthotech reported a net loss of $39.6 million, or $1.14 per diluted share, in the third quarter compared with a net income of $8.6 million, or $0.25 per diluted share, in the third quarter of 2014, according to a press release. The 2014 income was at…
Astellas to acquire Ocata
Astellas Pharma has entered into a definitive agreement to acquire Ocata Therapeutics, according to a press release. Astellas will acquire Ocata through Laurel Acquisition, a wholly owned subsidiary of Astellas. Laurel will commence a tender offer for all outstanding shares of Ocata’s common stock for $8.50 per share in cash.
VIDEO: Confessions of a new user of femtosecond laser
NEW YORK — At OSN New York 2015, Jennifer Loh, MD, shares her experence with femtosecond lasers for corneal incisions during cataract surgery.